Shen et al. show that pre-existing neural similarity in strangers predicts future friendship and changes in social distance over time in an emerging social network of MBA students.
Category: neuroscience – Page 37
Novel predictors of tumor growth by exploratory quantitative analysis of radiomics features from MRI data for incidentally discovered meningioma
Predicting future tumor growth from initial imaging of incidentally discovered meningioma (IDM) could inform treatment decisions. However, most factors identified in prior studies on meningioma growth are qualitative. The aim of this study is to identify factors associated with tumor growth using quantitative radiomics features from MRI data.
MRI T2 features from initial imaging of 24 tumor growth cases were compared with those of 25 cases without growth. An in-house program was developed to reduce the time required for data analysis. This program is based on the open-source software 3D Slicer 5.6.2 and PyRadiomics 3.1.0. It enables semi-automatic batch t-test analyses for each feature to compare tumor growth and non-growth groups. Regions of interest (ROIs) were placed in the tumor, outer tumor edge, whole brain, and white matter contralateral to the tumor. A total of 107 features were analyzed across seven classifications: First Order, Shape, Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, Gray Level Dependence Matrix, and Neighboring Gray Tone Difference Matrix. A t-test was used to identify significant predictors.
Ten features across five classifications showed significant differences (p 0.05): 2 First Order statistics, 2 Shape features, 4 Gy Level Co-occurrence Matrices, 1 Gy Level Size Zone Matrix, and 1 Neighboring Gray Tone Difference Matrix.
Nasal spray with gold nanoparticles delivers targeted treatment to the brain
Tiny gold particles that act as carriers for lithium can be delivered directly to the brain in the form of a nasal spray. Developed by scientists at the Università Cattolica Rome campus/Fondazione Policlinico Universitario A. Gemelli IRCCS, the new nanotechnological device can be used for the treatment and prevention of neuropsychiatric and neurodegenerative diseases.
Lithium is already in clinical use for manic-depressive syndrome, but in oral formulation it is not free of side effects. It is used to combat neuropsychiatric diseases such as bipolar disorder, neurodegenerative diseases such as Alzheimer’s disease, and brain infections such as those caused by Herpes Simplex Virus type 1, which several recent studies have linked to an increased risk of neurological diseases.
Published in the journal Advanced Materials and already patented, the idea is the result of a study that demonstrated that it is possible to directly inhibit the activity of an enzyme that plays a key role in the development of these diseases (glycogen synthase kinase-3 beta, GSK-3β) directly in the brain by using lithium delivered by intranasally administered gold nanoparticles.
From trips to treatments: how psychedelics could revolutionise anti-inflammatory medicine
Once synonymous with hippies and hallucinatory experiences, psychedelic drugs are now being explored for their medical potential. The stigma of that era resulted in research being suppressed by drug laws, yet with mental health treatments hitting limits, scientists have returned to this controversial corner of medicine.
Substances like psilocybin (found in magic mushrooms) and ayahuasca are now being taken seriously by scientists and doctors, not for the visions they induce, but for the healing potential they possess.
Initially, this focused on treating mental health conditions like depression, where currently prescribed drugs only help a minority of patients. But these investigations have now expanded to include diseases driven by inflammation, which psychedelic drugs may help reduce by calming down the immune system.
Magic mushrooms and LSD may do more than bend minds: they could fight inflammation linked to depression, arthritis and heart disease.
For the first time, scientists pinpoint brain cells linked to depression
Scientists identified two types of brain cells, neurons and microglia, that are altered in people with depression. Through genomic mapping of post-mortem brain tissue, they found major differences in gene activity affecting mood and inflammation. The findings reinforce that depression has a clear biological foundation and open new doors for treatment development.
Scientists create nanofluidic chip with ‘brain-like’ memory pathways
Scientists at Monash University have created a tiny fluid-based chip that behaves like neural pathways of the brain, potentially opening the door to a new generation of computers.
Roughly the size of a coin, the chip was built from a specially designed metal-organic framework (MOF), and channels ions through tiny pathways, mimicking the on/off switching of electronic transistors in computers.
But unlike conventional computer chips, it can also “remember” previous signals, mimicking the plasticity of neurons in the brain.
Receptor in cerebellum provides new insights into molecular basis of ataxia
Researchers at Ruhr University Bochum, Germany, identified a receptor that plays a crucial role in stress-induced motor incoordination associated with ataxias. These hereditary motor disorders have long been linked to the neurotransmitter norepinephrine.
The team, led by Dr. Pauline Bohne and Professor Melanie Mark from the Behavioral Neurobiology Working Group in Bochum, has now shown that the α1D norepinephrine receptor in the cerebellum is responsible for the symptoms. The team published these findings in the journal Cellular and Molecular Life Sciences on October 6, 2025.
People with ataxia experience recurring episodes of motor incoordination, also known as dystonia. These phases are triggered by various factors, such as physical or emotional stress, fever, alcohol, or caffeine. The episodes are triggered by the release of norepinephrine in the cerebellum, which is the most important brain region for coordinating movement. Currently, there is no cure for ataxia. Therefore, researchers want to gain a better understanding of the underlying mechanisms to find new treatment approaches.
Scientists discover brain circuit that can switch off chronic pain
Scientists have pinpointed Y1 receptor neurons in the brain that can override chronic pain signals when survival instincts like hunger or fear take precedence. Acting like a neural switchboard, these cells balance pain with other biological needs. The research could pave the way for personalized treatments that target pain at its brain source—offering hope for millions living with long-term pain.